Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

#1231

Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.

Aim(s): To raise awareness of the burden of NETs on pts’ daily lives by tumor location.

Materials and methods: Anonymous survey of NET pts from >12 countries conducted by INCA/Novartis in 2014 (Americas, Asia, Europe, Oceania) on the NET pt experience, including impact of NETs on pts’ lives. All comparisons are significant at the P<0.05 level. This NET patient survey was a collaboration between INCA and Novartis and the survey was funded by Novartis.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Ruszniewski P, Yao J, Kolarova T, Goldstein G, Sissons M,

Keywords: Symptom burden,